Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-20

Study Completion Date

2021-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Thoracic radiotherapy concurrent with chemotherapy stands for the standard regime for limited staged small cell lung cancer. Involved node radiation（INF） replaced elective node irradiation（ENI） as the more popular since several trails compared the two regimes. simultaneous integrated boost IMRT becomes mature with advancing in IMRT and VMAT. The investigator hypothesis that SIB-IMRT can confine the dose for organs at risk to reduce the toxicities compared with routine IMRT in limited disease small-cell lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC

NCT02738723

Small Cell Lung Cancer

UNKNOWN PHASE2

The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT

NCT01817023

Nasopharyngeal Carcinoma

UNKNOWN PHASE3

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

NCT03214003

Small Cell Lung Cancer Limited Stage Radiotherapy

COMPLETED NA

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NCT05615142

NSCLC Low Dose Radiotherapy Stereotactic Body Radiotherapy +1 more

RECRUITING PHASE1

Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03

NCT03328234

IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients recruited divided into two arms：SIB-IMRT or routine IMRT，in the routine arm，the prescription dose was 60Gy/2Gy/30f，and in the SIB arm ，60Gy was given to the field of the tumor and metastatic lymph nodes，50Gy was given to CR lesion and high-risk prevention. The physical advantages of SIB-IMRT are to reduce the radiation dose of organs that are at risk in the lungs, esophagus, and heart ensuring the adequate dose for tumor area at the same time. The investigators are carrying out this trial to compare the efficacy, safety, side effects, and type of failure of the two radiotherapy techniques, which will provide a new choice and reliable basis for the future dose-segmentation study of limited-stage small-cell lung cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small-cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SIB-IMRT

patients received radiotherapy using IMRT or VMAT，60Gy is given to the field of tumor and metastatic lymph nodes and 50Gy given to CR lesion and high-risk area.concurrent or sequential with 4-6 circles of chemotherapy of EP.

Group Type ACTIVE_COMPARATOR

SIB-IMRT

Intervention Type RADIATION

60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time

routine

patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy

Group Type OTHER

routine IMRT

Intervention Type RADIATION

patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SIB-IMRT

60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time

Intervention Type RADIATION

routine IMRT

patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-70 years old,KPS≥80
* pathological small cell lung cancer
* staged as limited disease SCLC（contralateral hilar invasion not included）
* receive radiotherapy concurrent or sequential with chemotherapy，if induction chemotherapy，got PR or SD
* no other tumors
* No serious medical diseases and dysfunction of major organs
* understand this study，able to complete the treatment，accept the following up and sign the informed consent
* Contraception in women of childbearing age.

Exclusion Criteria

* other malignant tumor（historically or simultaneously）curable non-melanoma skin cancer and cervical carcinoma in situ not included
* Uncontrolled heart disease or myocardial infarction within 6 months
* History of mental illness
* Pregnancy or Lactation
* uncontrolled diabetes、hypertension

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes